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8LETTER TO THE EDITOR
rythema Nodosum Secondary to Granulocyte
olony-Stimulating Factor in a Patient with Hodgkin
ymphoma during CD34 Cell Mobilization for
utologous Peripheral Blood Stem Cell
ransplantation: A Dose-Mediated Effect
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hStem cell mobilization techniques incorporate
ranulocyte colony-stimulating factor (G-CSF) alone,
n combination with chemotherapy, or with other cy-
okines. A variety of cutaneous disorders have been
escribed with G-CSF, including Sweet’s syndrome,
yoderma gangrenosum, and necrotizing vasculitis.
rythema nodosum (EN) is a rarely described cuta-
eous disorder related to G-CSF administration.
A 28-year-old man with nodular sclerosing
odgkin lymphoma was initially diagnosed with ad-
anced disease. He did not attain a complete remission
ith doxorubicin, bleomycin, vinblastine, and dacar-
azine (ABVD). Salvage therapies consisted of gem-
itabine-vinorelbine and etoposide, methylpred-
isolone, cytarabine, and cisplatin (ESHAP). He
resented to our service for an autologous peripheral
lood stem cell transplantation. In the event that the
atient required tandem transplantation, we aimed to
arvest a total of 10  106 CD34 cells per kilogram.
obilization 1 consisted of G-CSF 12 g/kg/d  5
ays, which yielded 4.68  106 CD34 cells per kilo-
ram. Mobilization 2 consisted of ifosfamide, carbo-
latin, and etoposide (ICE) plus G-CSF (12 g/kg/d).
his procedure was complicated by a catheter-related
nfection, and the harvest was stopped. Mobilization 3
as identical to mobilization 1 (G-CSF 12 g/kg/d 
days) and yielded 6.2  106 CD34 cells per kilo-
ram.
After completion of mobilization 3, the patient
omplained of multiple painful bilateral lower extrem-
ty lesions. The patient also reported similar lesions
fter the ﬁrst stem cell mobilization but had neglected
o inform his physicians. Physical examination re-
ealed multiple indurated, erythematous plaques on
he shins and posterior calves bilaterally, with the
argest measuring 5  4 cm.
Dermatology was consulted, and a diagnosis of
-CSF–induced EN was rendered. A skin biopsy was
ot performed because of the typical clinical ﬁndings n
16ssociated with EN. The patient was treated with
onsteroidal anti-inﬂammatory drugs, ice, and bed
est, and the lesions resolved within 3 days of cessation
f G-CSF. Subsequent treatment with a lower dose of
-CSF (5 g/kg/d) after transplantation did not result
n any further cutaneous ﬁndings.
Various skin disorders have been reported after
he administration of G-CSF. Although there are sev-
ral reported cases of G-CSF–induced Sweet’s syn-
rome, our literature review revealed 3 case reports of
anniculitis, such as EN, associated with G-CSF ad-
inistration [1-3]. EN is most often related to under-
ying infectious etiologies, but it has been uncom-
only associated with malignancies such as Hodgkin
ymphoma [4].
Both Sweet’s syndrome and EN are marked by an
nﬂammatory inﬁltrate without an associated vasculi-
is. However, there are clear clinical differences be-
ween the 2 disorders that can allow diagnosis on the
asis of physical examination. Sweet’s syndrome usu-
lly presents as papules or vesicles that reﬂect its
ermal involvement, whereas EN classically involves
odules/plaques. In addition, Sweet’s syndrome most
ften involves the face, neck, and upper extremities,
hereas EN usually involves the pretibial areas [5]. If
he diagnosis of EN or Sweet’s syndrome is unclear, a
iopsy should be undertaken, because the lesions with
weet’s syndrome may require steroid administration.
To our knowledge, this is the ﬁrst reported case of
N in a patient undergoing stem cell mobilization
ith G-CSF. Our case adds credence to a dose-medi-
ted effect for G-CSF–induced skin lesions [1]. Typ-
cally the lesions resolve after cessation of G-CSF, and
esolution can be related to increasing doses of the
rug. The pathogenesis of these lesions remains un-
lear but may be related to the cellular environment
reated with an increase in neutrophils. It has been
ypothesized that these lesions may be caused by a
eutrophil recovery syndrome in which an increase in
n
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EN Secondary to G-CSF
Beutrophils, either spontaneous or drug-induced, may
ead to cytokine release and upregulation of certain
dhesion molecules that culminates in accumulation
f neutrophils in the dermis [6]. It is clear that there
ust be a high clinical suspicion of cutaneous involve-
ent with G-CSF administration given the wide va-
iety of skin disorders, including EN, associated with
he drug.
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